Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Oncologist. 2020 Aug 30;:
Authors: Rosenberg AJ, Vokes EE
Abstract
Treatment of locoregionally advanced head and neck squamous cell carcinoma involves a multidisciplinary approach that combines surgery, radiotherapy, and systemic therapy. These curative strategies are associated with significant acute and long-term toxicities. With the emergence of human papillomavirus (HPV) as an etiologic factor associated primarily with oropharyngeal squamous cell carcinoma, higher cure rates juxtaposed with substantial treatment-related morbidity and mortality has led to interest in de-escalated therapeutic strategies, with the goal of optimizing oncologic outcomes while reducing treatment-related toxicity. Currently explored strategies include replacing, reducing, or omitting cytotoxic chemotherapy; reducing dose or volume of radiotherapy; and incorporation of less-invasive surgical approaches. Potential biomarkers to select patients for treatment de-escalation include clinical risk stratification, adjuvant de-escalation based on pathologic features, response to induction therapy, and molecular markers. The optimal patient selection and de-escalation strategy is critically important in the evolving treatment of locoregional head and neck cancer. Recently, two large phase III trials, RTOG 1016 and De-ESCALaTE, failed to de-escalate treatment in HPV-associ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Rosenberg AJ, Vokes EE Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Erbitux | Genital Warts | Head and Neck Cancer | HNSCC | HPV Testing | Human Papillomavirus (HPV) | Oropharyngeal Cancer | Skin Cancer | Sports Medicine | Squamous Cell Carcinoma | Toxicology